{
    "id": 17654,
    "fullName": "ERBB2 L841V",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) L841V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L841V has not been biochemically characterized, but in two different cell lines, L841V induced increased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785) and demonstrated transformation in cell culture (PMID: 29967253) and therefore, is predicted to result in a gain of Erbb2 (Her2) protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 11774,
                    "pubMedId": 29967253,
                    "title": "High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29967253"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "L841V",
    "createDate": "02/03/2016",
    "updateDate": "10/21/2019",
    "referenceTranscriptCoordinates": {
        "id": 170619,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39725076C>G",
        "cDna": "c.2521C>G",
        "protein": "p.L841V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13222,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 2.8 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 17958,
                "profileName": "ERBB2 L841V"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13233,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).",
            "molecularProfile": {
                "id": 17958,
                "profileName": "ERBB2 L841V"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10997,
                    "pubMedId": 29420467,
                    "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29420467"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17958,
            "profileName": "ERBB2 L841V",
            "profileTreatmentApproaches": [
                {
                    "id": 18529,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB2 L841V"
                },
                {
                    "id": 18530,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB2 L841V"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170619,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39725076C>G",
            "cDna": "c.2521C>G",
            "protein": "p.L841V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170620,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39725076C>G",
            "cDna": "c.2521C>G",
            "protein": "p.L841V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}